Raschi E, Antonazzo IC, La Placa M, Ardizzoni A, Poluzzi E, De Ponti F., Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System., «THE ONCOLOGIST», 2019, 24, pp. e1228 - e1231 [Scientific article]
Raschi E.; De Ponti F., Strategies for early prediction and timely recognition of drug-induced liver injury: The case of cyclin-dependent kinase 4/6 inhibitors, «FRONTIERS IN PHARMACOLOGY», 2019, 10, Article number: 1235 , pp. 1 - 15 [Scientific article]Open Access
Raschi E.; Mazzarella A.; Antonazzo I.C.; Bendinelli N.; Forcesi E.; Tuccori M.; Moretti U.; Poluzzi E.; De Ponti F., Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System, «TARGETED ONCOLOGY», 2019, 14, pp. 205 - 221 [Scientific article]Open Access
Dothel, Giovanni; Barbaro, Maria Raffaella; Raschi, Emanuel; Barbara, Giovanni; De Ponti, Fabrizio*, Advancements in drug development for diarrhea-predominant irritable bowel syndrome, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2018, 27, pp. 251 - 263 [Scientific article]
Raschi, Emanuel*; Girardi, Anna; Poluzzi, Elisabetta; Forcesi, Emanuele; Menniti-Ippolito, Francesca; Mazzanti, Gabriela; De Ponti, Fabrizio, Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems, «DRUG SAFETY», 2018, 41, pp. 745 - 752 [Scientific article]
Raschi, Emanuel; Diemberger, Igor; Cosmi, Benilde; De Ponti, Fabrizio, ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations, «INTERNAL AND EMERGENCY MEDICINE», 2018, 13, pp. 1 - 9 [Scientific article]
Raschi E.; Diemberger I.; Cosmi B.; De Ponti F., ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations—authors’ reply, «INTERNAL AND EMERGENCY MEDICINE», 2018, 13, pp. 635 - 636 [Comment or similar]
Mouchet, Julie; Salvo, Francesco; Raschi, Emanuel; Poluzzi, Elisabetta; Antonazzo, Ippazio Cosimo; De Ponti, Fabrizio; Bégaud, Bernard, Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis, «VACCINE», 2018, 36, pp. 1548 - 1555 [Scientific article]
Mouchet, Julie; Salvo, Francesco; Raschi, Emanuel; Poluzzi, Elisabetta; Antonazzo, Ippazio Cosimo; De Ponti, Fabrizio; Bégaud, Bernard, Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis, «PHARMACOLOGICAL RESEARCH», 2018, 132, pp. 108 - 118 [Scientific article]
Antonazzo, Ippazio Cosimo; Raschi, Emanuel; Forcesi, Emanuele; Riise, Trond; Bjornevik, Kjetil; Baldin, Elisa; De Ponti, Fabrizio; Poluzzi, Elisabetta, Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System, «EXPERT OPINION ON DRUG SAFETY», 2018, 17, pp. 869 - 874 [Scientific article]
Mei, Riccardo; Raschi, Emanuel; Forcesi, Emanuele; Diemberger, Igor; De Ponti, Fabrizio; Poluzzi, Elisabetta, Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System, «INTERNATIONAL JOURNAL OF CARDIOLOGY», 2018, 273, pp. 183 - 186 [Scientific article]
Carnovale, Carla; Raschi, Emanuel; Leonardi, Luca; Moretti, Ugo; De Ponti, Fabrizio; Gentili, Marta; Pozzi, Marco; Clementi, Emilio; Poluzzi, Elisabetta; Radice, Sonia, No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase, «EXPERT REVIEW OF VACCINES», 2018, 17, pp. 363 - 381 [Scientific article]
Raschi, Emanuel*; Poluzzi, Elisabetta; Fadini, Gian Paolo; Marchesini, Giulio; De Ponti, Fabrizio, Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?, «DIABETES, OBESITY AND METABOLISM», 2018, 20, pp. 2711 - 2723 [Scientific article]Open Access
Raschi, Emanuel; Mazzotti, Arianna; Poluzzi, Elisabetta; De Ponti, Fabrizio; Marchesini, Giulio*, Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease, «EXPERT OPINION ON PHARMACOTHERAPY», 2018, 19, pp. 1903 - 1914 [Scientific article]
Raschi, E.; Poluzzi, E.*; Salvo, F.; Pariente, A.; De Ponti, F.; Marchesini, G.; Moretti, U., Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems, «NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES», 2018, 28, pp. 533 - 542 [Scientific article]
